SE434680B - Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning - Google Patents
Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemningInfo
- Publication number
- SE434680B SE434680B SE8300320A SE8300320A SE434680B SE 434680 B SE434680 B SE 434680B SE 8300320 A SE8300320 A SE 8300320A SE 8300320 A SE8300320 A SE 8300320A SE 434680 B SE434680 B SE 434680B
- Authority
- SE
- Sweden
- Prior art keywords
- monoclonal
- cells
- blood group
- monoclonal antibodies
- polyclonal
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 title claims description 28
- 239000008280 blood Substances 0.000 title claims description 28
- 239000012266 salt solution Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 235000002639 sodium chloride Nutrition 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 210000003743 erythrocyte Anatomy 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 7
- 230000035931 haemagglutination Effects 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 16
- 230000004927 fusion Effects 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 241000237369 Helix pomatia Species 0.000 description 1
- 241000219822 Macrotyloma axillare Species 0.000 description 1
- 235000001504 Macrotyloma uniflorum var. uniflorum Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011511 automated evaluation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000001492 haemagglutinating effect Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8300320A SE434680B (sv) | 1983-01-21 | 1983-01-21 | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
| EP84850009A EP0115476B1 (de) | 1983-01-21 | 1984-01-10 | Monoklonalantikörperabfassung für diagnostischen Gebrauch |
| DE8484850009T DE3485289D1 (de) | 1983-01-21 | 1984-01-10 | Monoklonalantikoerperabfassung fuer diagnostischen gebrauch. |
| AT84850009T ATE69891T1 (de) | 1983-01-21 | 1984-01-10 | Monoklonalantikoerperabfassung fuer diagnostischen gebrauch. |
| US06/570,264 US4618486A (en) | 1983-01-21 | 1984-01-12 | Monoclonal antibody formulation for diagnostic use |
| JP59008372A JPH0654316B2 (ja) | 1983-01-21 | 1984-01-20 | 診断用モノクロナル抗体製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8300320A SE434680B (sv) | 1983-01-21 | 1983-01-21 | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8300320D0 SE8300320D0 (sv) | 1983-01-21 |
| SE8300320L SE8300320L (sv) | 1984-07-22 |
| SE434680B true SE434680B (sv) | 1984-08-06 |
Family
ID=20349708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8300320A SE434680B (sv) | 1983-01-21 | 1983-01-21 | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4618486A (de) |
| EP (1) | EP0115476B1 (de) |
| JP (1) | JPH0654316B2 (de) |
| AT (1) | ATE69891T1 (de) |
| DE (1) | DE3485289D1 (de) |
| SE (1) | SE434680B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764465A (en) * | 1984-04-26 | 1988-08-16 | Cetus Corporation | Human monoclonal antibody against group A red blood cells |
| DE3686474T2 (de) * | 1985-10-11 | 1993-02-11 | Abbott Lab | Diagnostische probe. |
| US4695553A (en) * | 1985-11-01 | 1987-09-22 | Becton Dickinson And Co., Inc. | Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample using antibodies |
| US4837170A (en) * | 1986-01-20 | 1989-06-06 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibody, measuring method of glucosylated protein by utilizing the monoclonal antibody, and kit therefor |
| DE3901458A1 (de) * | 1989-01-19 | 1990-07-26 | Behringwerke Ag | Verwendung von zwei- oder dreiwertigen kationen in immunchemischen tests |
| DE4035174A1 (de) * | 1990-11-06 | 1992-05-07 | Biotest Ag | Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2004039337A2 (en) * | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| EP1660186B1 (de) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanisierung von antikörpern |
| WO2005121322A1 (en) * | 2004-06-11 | 2005-12-22 | Kiwi Ingenuity Limited | Enzymatic modification of cell-surface h antigen by glycosyltransferases |
| EP1869192B1 (de) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Rahmenmischung von antikörpern |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
| EP2625203A1 (de) | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen |
| LT2953969T (lt) | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| EP3161001A2 (de) | 2014-06-25 | 2017-05-03 | Novartis AG | Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind |
| JP6993699B2 (ja) | 2016-01-11 | 2022-02-03 | ウニヴェルズィテート・ツューリヒ | ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質 |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164558A (en) * | 1976-11-22 | 1979-08-14 | Massachusetts Institute Of Technology | Method for optimizing reagents for agglutination reactions |
| US4319882A (en) * | 1980-02-21 | 1982-03-16 | Yash Sharma | Method for detecting immunological agglutination and biochemical agent therefor |
| DE3235924T1 (de) * | 1981-03-06 | 1983-05-05 | Celltech Ltd., Slough, Berkshire | Monoklonaler antikoerper |
| WO1982003462A1 (en) * | 1981-03-27 | 1982-10-14 | Ltd Biospecia | Immunological analysis and a biochemical agent therefore |
| EP0061541A1 (de) * | 1981-03-27 | 1982-10-06 | Biospecia Limited | Immunologische Analyse und biochemisches Mittel hierfür |
| GB2117789B (en) * | 1982-03-29 | 1985-08-29 | East Anglian Regional Health | Abo blood grouping reagent |
| GB2127434A (en) * | 1982-09-17 | 1984-04-11 | Univ London | A human monoclonal antibody against Rhesus D antigen |
-
1983
- 1983-01-21 SE SE8300320A patent/SE434680B/sv not_active IP Right Cessation
-
1984
- 1984-01-10 DE DE8484850009T patent/DE3485289D1/de not_active Revoked
- 1984-01-10 AT AT84850009T patent/ATE69891T1/de not_active IP Right Cessation
- 1984-01-10 EP EP84850009A patent/EP0115476B1/de not_active Expired - Lifetime
- 1984-01-12 US US06/570,264 patent/US4618486A/en not_active Expired - Fee Related
- 1984-01-20 JP JP59008372A patent/JPH0654316B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4618486A (en) | 1986-10-21 |
| EP0115476B1 (de) | 1991-11-27 |
| JPH0654316B2 (ja) | 1994-07-20 |
| ATE69891T1 (de) | 1991-12-15 |
| DE3485289D1 (de) | 1992-01-09 |
| SE8300320L (sv) | 1984-07-22 |
| EP0115476A2 (de) | 1984-08-08 |
| EP0115476A3 (en) | 1988-10-12 |
| SE8300320D0 (sv) | 1983-01-21 |
| JPS59138959A (ja) | 1984-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0115476B1 (de) | Monoklonalantikörperabfassung für diagnostischen Gebrauch | |
| Schumacher et al. | Detection of antibodies to a pathogenic mycoplasma in desert tortoises (Gopherus agassizii) with upper respiratory tract disease | |
| Rosengarten et al. | Antigen heterogeneity among isolates of Mycoplasma bovis is generated by high-frequency variation of diverse membrane surface proteins | |
| Reth et al. | Analysis of the repertoire of anti‐NP antibodies in C57BL/6 mice by cell fusion. I. Characterization of antibody families in the primary and hyperimmune response | |
| US4562003A (en) | Monoclonal antibodies against alveolar surfactant protein | |
| JP5903381B2 (ja) | 抗ｆｄｐモノクローナル抗体、それを用いたｆｄｐ測定用試薬及び試薬キット、並びにｆｄｐ測定方法 | |
| EP0161638A2 (de) | Monoklonaler Antikörper und Verfahren zur quantitativen Bestimmung von Immunoglobulinen mittels dieses Antikörpers | |
| Youinou et al. | Specificity of Plasma Cells in the Rheumatoid Synovium: I. Immunoglobulin Class of Antiglobulin‐Producing Cells | |
| Espelid et al. | Monoclonal antibodies against Vibrio salmonicida: the causative agent of coldwater vibriosis (‘Hitra disease’) in Atlantic salmon, Salmo salar L. | |
| AU616384B2 (en) | Method for the evaluation of oral microbes | |
| Zharhary et al. | The frequency and fine specificity of B cells responsive to (4-hydroxy-3-nitrophenyl) acetyl in aged mice | |
| Padmanabhan et al. | Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience | |
| WO1995033758A1 (en) | Novel glyceroglycophospholipid, antibody there against, and method of detecting mycoplasma | |
| Messeter et al. | Immunochemical characterization of a monoclonal anti‐Leb blood grouping reagent | |
| Kobayashi et al. | Characterization of Monoclonal Antibodies against fEtiological Agents of Weil's Disease | |
| RU2395576C1 (ru) | ШТАММ ГИБРИДНЫХ КЛЕТОК ЖИВОТНОГО Mus musculus L.1B2 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ДЛЯ ВЫЯВЛЕНИЯ НУКЛЕОПРОТЕИНА ВИРУСА ЭБОЛА, СУБТИП ЗАИР (ШТАММ Mainga) (ВАРИАНТЫ), МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПРОДУЦИРУЕМОЕ ШТАММОМ (ВАРИАНТЫ), НАБОР ДЛЯ ИММУНОФЕРМЕНТНОЙ ТЕСТ-СИСТЕМЫ ФОРМАТА "СЭНДВИЧ" ДЛЯ ВЫЯВЛЕНИЯ НУКЛЕОПРОТЕИНА ВИРУСА ЭБОЛА, СУБТИП ЗАИР (ШТАММ Mainga) | |
| Morrison-Plummer et al. | An ELISA to detect monoclonal antibodies specific for lipid determinants of Mycoplasma pneumoniae | |
| DE69519699T2 (de) | Inhibitor und anti-Inhibitor monoklonale Antikörper gegen Meerrettichperoxidase | |
| Magee et al. | Monoclonal antibodies specific for Corynebacterium sepedonicum, the causative agent of potato ring rot | |
| Gerstenecker et al. | Development of a capture-ELISA for the specific detection of Mycoplasma pneumoniae in patients’ material | |
| Thompson et al. | Human monoclonal antibodies to human blood group antigens Kidd Jka and Jkb | |
| Fraser et al. | MOUSE MONOCLONAL ANTI‐N: II. PHYSICOCHEMICAL CHARACTERIZATION AND ASSESSMENT FOR ROUTINE BLOOD GROUPING | |
| Seifert et al. | Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria | |
| Abe et al. | Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups | |
| Komisar et al. | Monoclonal antibodies to Salmonella typhimurium and Escherichia coli lipopolysaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8300320-2 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8300320-2 Format of ref document f/p: F |